VIVES is a multi-sector fund that invests in projects with a positive societal impact
In 1957 mankind sent the first object to Space in its goal to reach further. In the last 60 years the amount of man-made objects sent into Space has grown exponentially. However, most of these objects...
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (Belgium) and the University of Wageningen...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its
Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares
Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes